The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment
Open accessAbstract
Background Remimazolam is a new benzodiazepine for procedural sedation and general anaesthesia. The aim of this study was to characterise its pharmacokinetic properties and safety in renally and hepatically impaired subjects. Methods Two separate trials were conducted in patients with hepatic ( n =11) or renal impairment ( n =11) compared with matched healthy subjects ( n =9 and n =12, respectively). The hepatic impairment trial was an open-label adaptive ‘Reduced Design' trial, using a single bolus of remimazolam 0.1 mg kg −1 i.v., whereas the renal impairment trial was an open-label trial of a single bolus dose of remimazolam 1.5 mg i.v. Remimazolam plasma concentrations over time were analysed by population pharmacokinetic modelling. Results Remimazolam pharmacokinetic properties were adequately described by a three-compartment, recirculatory model. Exposure in subjects with severe hepatic impairment was 38.1% higher (i.e. clearance was 38.1% lower) compared with healthy volunteers. This increase caused a slightly delayed recovery (8.0 min for healthy, 12.1 min for moderate, and 16.7 min for severe hepatic impairment). With renal impairment, plasma clearance was comparable with that measured in healthy subjects. Simulations of C max after a bolus dose of 10 mg showed no relevant impact of hepatic or renal impairment. The overall incidence of adverse events was low, and all adverse events were mild. Conclusions As C max after a remimazolam bolus i.v. was not affected by hepatic or renal impairment, no dose adjustments are required. No unexpected adverse events related to remimazolam were seen in subjects with renal or hepatic impairment. Clinical trial registration Hepatic impairment trial: ClinicalTrials.gov, NCT01790607 (https://clinicaltrials.gov/ct2/show/NCT01790607). Renal impairment trial: EudraCT Number: 2014-004575-23.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wiltshire, H. R., Kilpatrick, G. J., Tilbrook, G. S., & Borkett, K. M. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318241f68a · Cited by 215
Self-citation
Cited by
Remimazolam: pharmacological characteristics and clinical applications in anesthesiology
Kim, K. M. (2022) · Anesthesia and Pain Medicine · doi:10.17085/apm.21115 · Cited by 257
Mao, Y., Guo, J., Yuan, J., Zhao, E., & Yang, J. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s359496 · Cited by 122
WEGNER, B. M., WEGNER, G. M., SPAGNOL, L. W., COSTA, L. A., SPAGNOL, V. W., & PAIVA, D. F. (2024) · Minerva Anestesiologica · doi:10.23736/s0375-9393.24.18041-8 · Cited by 19
Cui, L., Shu, K., Zhang, P., Cui, Q., & Yun, H. (2023) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/2023/9955312 · Cited by 3
Metadata
- Authors
- Stöhr, T., Colin, P. J., Ossig, J., Pesic, M., Borkett, K., Winkle, P., Struys, M. M. R. F., & Schippers, F.
- Venue
- British Journal of Anaesthesia
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 127
- Issue
- 3
- Pages
- 415-423
- ISSN
- 0007-0912 (ISSN-L)
- OpenAlex
- W3179504841
- Cited by
- 207
- References
- 1
- FWCI
- 31.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. https://app.cochat.ai/papers/10.1016/j.bja.2021.05.027
- The paper
- Stöhr, T., Colin, P. J., Ossig, J., Pesic, M., Borkett, K., Winkle, P., Struys, M. M. R. F., & Schippers, F. (2021). Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2021.05.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.